Oppenheimer Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Oppenheimer Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-185	Closed	-$36K	–	1207
2020 Q1	$36K	Buy	+185	New	+$39.8K	﹤0.01%	1303
2017 Q4	–	Sell	-53	Closed	-$5K	–	1225
2017 Q3	$5K	Buy	53 +6	+13%	+$524	﹤0.01%	1571
2017 Q2	$4K	Hold	47	–	–	﹤0.01%	1573
2017 Q1	$4K	Buy	+47	New	+$3.38K	﹤0.01%	1602

Other funds holding LKFT

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Oppenheimer Asset Management's LKFT Position: Q2 2020 in Review

Oppenheimer Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2020, closing a stake of 185 shares — an estimated $36K sold.

Oppenheimer Asset Management first reported a position in LKFT in Q1 2017 and held it in 4 quarters. The position peaked at $36K in Q1 2020. 143 funds tracked by Wall St. Rank hold LKFT as of Q2 2020.

Oppenheimer Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2020 after selling out during the quarter.
Oppenheimer Asset Management sold 185 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2020, an estimated $36K.
Oppenheimer Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2017 and held it in 4 quarters.
Oppenheimer Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $36K in Q1 2020.
143 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2020.

Based on Oppenheimer Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.